CADL•benzinga•
Canaccord Genuity Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $20
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga